Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kd Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021
Leniolisib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kd Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021 ### Output: Leniolisib